Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Pediatr Hematol Oncol ; 39(3): 235-237, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27479018

RESUMEN

Deferesirox (DFX), an oral chelating agent, is used to treat chronic iron overload in several hematological diseases such as ß-thalassemia, sickle cell disease, and myelodysplastic anemia. DFX is generally well tolerated with the exception of gastrointestinal disturbances and rash, although cases of renal toxicity, as well as acute and chronic liver failure, have been reported in adults and children. Here we describe a 3-year-old girl with ß-thalassemia undergoing treatment with DFX who presented with acute liver failure and Fanconi's syndrome. It is important for pediatric gastroenterologists, hepatologists, and hematologists to be aware that the commonly used drug DFX can lead to acute liver failure in children, and liver function should be monitored closely in all patients taking DFX.


Asunto(s)
Benzoatos/toxicidad , Fallo Hepático Agudo/etiología , Triazoles/toxicidad , Talasemia beta/complicaciones , Benzoatos/uso terapéutico , Preescolar , Deferasirox , Síndrome de Fanconi , Femenino , Humanos , Fallo Hepático Agudo/inducido químicamente , Triazoles/uso terapéutico , Talasemia beta/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...